Axsome registers Phase 3 long-term safety study of Sunosi in pediatric ADHDAug 19Trial updateAxsome Therapeutics, Inc.solriamfetol
Axsome reports 2Q 2026 results, Alzheimer's agitation launch, AXS-12 NDA acceptedAug 10Quarterly updateAxsome Therapeutics, Inc.solriamfetol
Axsome registers two Phase 3 solriamfetol trials in pediatric and adolescent ADHDJul 21Weekly roundup, 2 itemsAxsome Therapeutics, Inc.solriamfetol
Sign inSign in